News

News

December 31, 2013

IMMUNOMEDICS ANNOUNCES U.S. PATENT FOR ANTIBODY-SN-38 CONJUGATES

December 9, 2013

IMMUNOMEDICS REPORTS PROMISING ACTIVITY WITH VELTUZUMAB IN RELAPSED IMMUNE THROMBOCYTOPENIA

December 4, 2013

IMMUNOMEDICS ANNOUNCES OUTCOME OF 2013 ANNUAL MEETING OF STOCKHOLDERS

December 4, 2013

IMMUNOMEDICS ANNOUNCES ORPHAN DRUG DESIGNATION FOR IMMU-132 FOR SMALL CELL LUNG CANCER THERAPY

December 3, 2013

IMMUNOMEDICS TO PRESENT AT OPPENHEIMER 24TH ANNUAL HEALTHCARE CONFERENCE

December 2, 2013

IMMUNOMEDICS ANNOUNCES PRESENTATIONS AT THE 2013 ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

November 8, 2013

IMMUNOMEDICS ANNOUNCES IMMU-132 IS ACTIVE IN PATIENTS REFRACTORY TO IRINOTECAN

November 5, 2013

IMMUNOMEDICS AWARDED KEY PATENT FOR TROP-2 ANTIBODY

November 4, 2013

IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

October 25, 2013

IMMUNOMEDICS ANNOUNCES 4 PRESENTATIONS ON EPRATUZUMAB AT 2013 AMERICAN COLLEGE OF RHEUMATOLOGY ANNUAL MEETING

October 25, 2013

EPRATUZUMAB’S MECHANISM OF ACTION FEATURED IN BLOOD, OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY

October 24, 2013

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST QUARTER FISCAL 2014 FINANCIAL RESULTS

October 23, 2013

IMMUNOMEDICS ANNOUNCES 90Y-CLIVATUZUMAB TETRAXETAN IN COMBINATION WITH LOW-DOSE GEMCITABINE IS ACTIVE IN PATIENTS WITH LATE-STAGE PANCREATIC CANCER

October 22, 2013

IMMUNOMEDICS DEVELOPS DENDRITIC-CELL VACCINE TECHNOLOGY FOR LYMPHOMAS AND LEUKEMIAS

October 22, 2013

IMMUNOMEDICS REPORTS MULTIPLE OBJECTIVE RESPONSES IN SOLID CANCERS WITH IMMU-132

October 10, 2013

IMMUNOMEDICS ANNOUNCES PRESENTATIONS AT UPCOMING CONFERENCES

October 9, 2013

IMMUNOMEDICS ANNOUNCES TERMINATION OF AGREEMENT AND RETURN OF WORLDWIDE RIGHTS TO VELTUZUMAB FOR ALL NON-CANCER INDICATIONS

September 30, 2013

IMMUNOMEDICS CONFIRMS FUNDING OF DEPARTMENT OF DEFENSE CLINICAL TRIAL GRANT FOR MILATUZUMAB IN LUPUS

September 30, 2013

IMMUNOMEDICS REPORTS UPDATED RESULTS OF LABETUZUMAB-SN-38 IN METASTATIC COLORECTAL CANCER

September 4, 2013

IMMUNOMEDICS TO PRESENT AT STIFEL HEALTHCARE CONFERENCE 2013

September 3, 2013

IMMUNOMEDICS APPOINTS PETER P. PFREUNDSCHUH AS NEW CHIEF FINANCIAL OFFICER

August 22, 2013

IMMUNOMEDICS ANNOUNCES FISCAL 2013 RESULTS

August 20, 2013

IMMUNOMEDICS APPOINTS RICHARD L SHERMAN TO BOARD OF DIRECTORS

August 14, 2013

EPRATUZUMAB AND RITUXIMAB PRODUCE HIGH RATE AND DURABLE PROGRESSION-FREE SURVIVAL IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

August 12, 2013

IMMUNOMEDICS ADVANCES SOLID TUMOR ANTIBODY-DRUG CONJUGATE PROGRAMS TO PHASE II CLINICAL TRIALS

August 9, 2013

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FOURTH QUARTER AND FISCAL YEAR 2013 FINANCIAL RESULTS

July 16, 2013

IMMUNOMEDICS CONSTRUCTS NEW HUMANIZED ANTIBODY FOR B-CELL MEDIATED CANCER AND AUTOIMMUNE DISEASES

July 03, 2013

IMMUNOMEDICS REPORTS FIRST RESULTS FROM PHASE IB STUDY OF 90Y-CLIVATUZUMAB IN PATIENTS WITH METASTATIC PANCREATIC CANCER AFTER 2 OR MORE PRIOR THERAPIES

June 14, 2013

IMMUNOMEDICS TO PRESENT AT WELLS FARGO SECURITIES 2013 HEALTHCARE CONFERENCE

June 13, 2013

IMMUNOMEDICS PRESENTS EPRATUZUMAB’S MECHANISM OF ACTION IN SYSTEMIC LUPUS ERYTHEMATOSUS

June 13, 2013

IMMUNOMEDICS REPORTS THAT UCB ANNOUNCES NEW RESULTS FROM PHASE 2B OPEN-LABEL EXTENSION STUDY EVALUATING THE LONG-TERM EFFECTS OF EPRATUZUMAB IN SLE

June 12, 2013

IMMUNOMEDICS REPORTS PROGRESS WITH LABELING PROTEINS,INCLUDING ANTIBODIES, FOR IMPROVED PET IMAGING

June 11, 2013

COMBINATION OF 90Y-EPRATUZUMAB AND VELTUZUMAB IS ACTIVE IN NON-HODGKIN LYMPHOMA

June 10, 2013

90Y-EPRATUZUMAB STUDY SHOWS IMPROVEMENT OF THERAPY RESULTS FOLLOWING R-CHOP

June 10, 2013

IMMUNOMEDICS DEVELOPS NOVEL DUAL SYSTEM FOR TUMOR DETECTION AND IMAGING

June 10, 2013

NEW DATA FROM EPRATUZUMAB TO BE PRESENTED AT EULAR 2013

June 03, 2013

IMMUNOMEDICS ANNOUNCES SIX PRESENTATIONS AT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2013 ANNUAL MEETING

May 30, 2013

IMMUNOMEDICS PRESENTS CLINICAL PROGRESS OF ANTIBODYDRUG CONJUGATE PROGRAMS AT CONFERENCE OF NEW YORK BIOTECHNOLOGY ASSOCIATION

May 29, 2013

IMMUNOMEDICS TO PRESENT AT JEFFERIES 2013 GLOBAL HEALTHCARE CONFERENCE

May 28, 2013

IMMUNOMEDICS INVENTS METHOD TO LABEL PEPTIDES AND OTHER PROTEINS, INCLUDING ANTIBODIES, WITH PET AND MRI IMAGING RADIONUCLIDES

May 08, 2013

IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2013 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

May 07, 2013

IMMUNOMEDICS ANNOUNCES THREE NEW PATENT AWARDS

April 25, 2013

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER FISCAL 2013 FINANCIAL RESULTS

April 10, 2013

IMMUNOMEDICS DEVELOPS T-CELL REDIRECTING BISPECIFIC ANTIBODIES AS POTENTIAL THERAPEUTICS FOR SOLID AND LIQUID TUMORS

April 9, 2013

IMMUNOMEDICS REPORTS FIRST RESULTS OF LABETUZUMAB-SN-38 IN COLORECTAL CANCER

April 8, 2013

IMMUNOMEDICS CREATES NOVEL ANTIBODY-CYTOKINE CONJUGATES FOR CANCER THERAPY

April 8, 2013

IMMUNOMEDICS ANNOUNCES CLIVATUZUMAB-BASED BLOOD TEST CAN DIFFERENTIATE BETWEEN PANCREATIC CANCER AND CHRONIC PANCREATITIS

April 1, 2013

IMMUNOMEDICS SETTLES FINRA ARBITRATION PROCEEDINGS RELATING TO ITS PRIOR INVESTMENT IN CERTAIN SECURITIES

April 1, 2013

IMMUNOMEDICS ANNOUNCES PRESENTATIONS AT THE 2013 ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

February 27, 2013

IMMUNOMEDICS ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF OVERALLOTMENT OPTION BY UNDERWRITERS

February 25, 2013

IMMUNOMEDICS TO PRESENT AT COWEN AND COMPANY 33RD ANNUAL HEALTH CARE CONFERENCE

February 22, 2013

IMMUNOMEDICS PRICES $14.0 MILLION PUBLIC OFFERING OF COMMON STOCK

February 21, 2013

IMMUNOMEDICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

February 7, 2013

IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2013 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS

January 28, 2013

IMMUNOMEDICS IN COLLABORATION WITH ALGETA TO EVALUATE POTENTIAL OF EPRATUZUMAB CONJUGATED TO ALPHA-EMITTER THORIUM-227

January 25, 2013

IMMUNOMEDICS ANNOUNCES CONFERENCE CALL AND WEBCAST FOR SECOND QUARTER FISCAL 2013 FINANCIAL RESULTS

January 8, 2013

IMMUNOMEDICS ANNOUNCES U.S. PATENT FOR HEXAVALENT DOCK-AND-LOCK™ COMPLEXES